174 related articles for article (PubMed ID: 28540524)
1. Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET.
Georg P; Andrzejewski P; Baltzer P; Daniel M; Wadsak W; Mitterhauser M; Sturdza A; Majercakova K; Karanikas G; Pötter R; Hacker M; Helbich T; Georg D; Pinker K
Mol Imaging Biol; 2018 Feb; 20(1):160-169. PubMed ID: 28540524
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric [18F]Fluorodeoxyglucose/ [18F]Fluoromisonidazole Positron Emission Tomography/ Magnetic Resonance Imaging of Locally Advanced Cervical Cancer for the Non-Invasive Detection of Tumor Heterogeneity: A Pilot Study.
Pinker K; Andrzejewski P; Baltzer P; Polanec SH; Sturdza A; Georg D; Helbich TH; Karanikas G; Grimm C; Polterauer S; Poetter R; Wadsak W; Mitterhauser M; Georg P
PLoS One; 2016; 11(5):e0155333. PubMed ID: 27167829
[TBL] [Abstract][Full Text] [Related]
3. Impact of hybrid PET/MR technology on multiparametric imaging and treatment response assessment of cervix cancer.
Daniel M; Andrzejewski P; Sturdza A; Majercakova K; Baltzer P; Pinker K; Wadsak W; Mitterhauser M; Pötter R; Georg P; Helbich T; Georg D
Radiother Oncol; 2017 Dec; 125(3):420-425. PubMed ID: 29153465
[TBL] [Abstract][Full Text] [Related]
4. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
[TBL] [Abstract][Full Text] [Related]
5.
Yu W; Qiao F; Su X; Zhang D; Wang H; Jiang J; Xu H
Biomed Pharmacother; 2019 Nov; 119():109454. PubMed ID: 31526971
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
[TBL] [Abstract][Full Text] [Related]
7. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
8. Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
Simoncic U; Leibfarth S; Welz S; Schwenzer N; Schmidt H; Reischl G; Pfannenberg C; Fougère C; Nikolaou K; Zips D; Thorwarth D
Med Phys; 2017 Jun; 44(6):2358-2368. PubMed ID: 28317128
[TBL] [Abstract][Full Text] [Related]
9. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
[TBL] [Abstract][Full Text] [Related]
10. Quantification of Tumor Hypoxic Fractions Using Positron Emission Tomography with [
Kelada OJ; Rockwell S; Zheng MQ; Huang Y; Liu Y; Booth CJ; Decker RH; Oelfke U; Carson RE; Carlson DJ
Mol Imaging Biol; 2017 Dec; 19(6):893-902. PubMed ID: 28409339
[TBL] [Abstract][Full Text] [Related]
11. Characterizing hypoxia in human glioma: A simultaneous multimodal MRI and PET study.
Preibisch C; Shi K; Kluge A; Lukas M; Wiestler B; Göttler J; Gempt J; Ringel F; Al Jaberi M; Schlegel J; Meyer B; Zimmer C; Pyka T; Förster S
NMR Biomed; 2017 Nov; 30(11):. PubMed ID: 28805936
[TBL] [Abstract][Full Text] [Related]
12. Machine learning identifies multi-parametric functional PET/MR imaging cluster to predict radiation resistance in preclinical head and neck cancer models.
Boeke S; Winter RM; Leibfarth S; Krueger MA; Bowden G; Cotton J; Pichler BJ; Zips D; Thorwarth D
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3084-3096. PubMed ID: 37148296
[TBL] [Abstract][Full Text] [Related]
13. Monitoring early response to chemoradiotherapy with
Grkovski M; Lee NY; Schöder H; Carlin SD; Beattie BJ; Riaz N; Leeman JE; O'Donoghue JA; Humm JL
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1682-1691. PubMed ID: 28540417
[TBL] [Abstract][Full Text] [Related]
14. ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.
Gerstner ER; Zhang Z; Fink JR; Muzi M; Hanna L; Greco E; Prah M; Schmainda KM; Mintz A; Kostakoglu L; Eikman EA; Ellingson BM; Ratai EM; Sorensen AG; Barboriak DP; Mankoff DA;
Clin Cancer Res; 2016 Oct; 22(20):5079-5086. PubMed ID: 27185374
[TBL] [Abstract][Full Text] [Related]
15. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
16.
Grkovski M; Emmas SA; Carlin SD
J Nucl Med; 2017 Oct; 58(10):1567-1573. PubMed ID: 28360207
[TBL] [Abstract][Full Text] [Related]
17. Early response of patients undergoing concurrent chemoradiotherapy for cervical cancer: a comparison of PET/CT and MRI.
Lee JE; Huh SJ; Nam H; Ju SG
Ann Nucl Med; 2013 Jan; 27(1):37-45. PubMed ID: 23054833
[TBL] [Abstract][Full Text] [Related]
18. Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
Bruehlmeier M; Roelcke U; Schubiger PA; Ametamey SM
J Nucl Med; 2004 Nov; 45(11):1851-9. PubMed ID: 15534054
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: Preliminary results.
Sarabhai T; Tschischka A; Stebner V; Nensa F; Wetter A; Kimmig R; Forsting M; Herrmann K; Umutlu L; Grueneisen J
Clin Imaging; 2018; 49():163-168. PubMed ID: 29554613
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An
Mainta IC; Zilli T; Tille JC; De Perrot T; Vallée JP; Buchegger F; Garibotto V; Miralbell R
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1210-1218. PubMed ID: 29678527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
